Asset profile

upadacitinib · AbbVie (ABBV)

Indication: non-segmental vitiligo
Also known as: Rinvoq, RINVOQ 15 mg tablet, weight-based 1 mg/mL oral solution

Company

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products…

Start live analysis of ABBV Run 8-agent AI analysis Stock overview

On the calendar

Sep 2026

Sep 30, 2026

31 days ago

Registry ID	Phase	Status	Primary completion	Enrollment	Sites
NCT07064889	Phase 2	Not yet recruiting	Jul 30, 2027	132	0 of 1 sites in the United States
NCT05121298	Phase 3	Unknown	Nov 30, 2023	155	0 of 1 sites in the United States
NCT07670156	Phase 1/2	Not yet recruiting	Aug 1, 2028	30	3 of 3 sites in the United States
NCT02925117	Phase 2	Completed	Aug 10, 2017	167	10 of 34 sites in the United States
NCT07588568	Phase 2	Recruiting	Feb 1, 2030	52	2 of 2 sites in the United States
NCT02675426	Phase 3	Completed	Apr 21, 2017	661	57 of 167 sites in the United States
NCT03345823	Phase 3	Active, not recruiting	Sep 1, 2027	747	123 of 466 sites in the United States
NCT05782907	Phase 3	Active, not recruiting	Aug 1, 2028	122	20 of 89 sites in the United States
NCT06227910	Phase 3	Recruiting	Jun 8, 2027	396	19 of 138 sites in the United States
NCT03569293	Phase 3	Completed	Jan 6, 2021	912	58 of 180 sites in the United States
NCT03006068	Phase 3	Active, not recruiting	Jul 1, 2027	950	147 of 492 sites in the United States
NCT07008846	Phase 3	Active, not recruiting	Sep 30, 2026	96	0 of 1 sites in the United States
NCT07080346	Phase 2	Completed	Dec 20, 2024	27	0 of 1 sites in the United States
NCT03178487	Phase 2	Completed	Jan 21, 2019	187	22 of 101 sites in the United States
NCT06012240	Phase 3	Recruiting	Apr 1, 2030	1500	78 of 272 sites in the United States
NCT06862284	Phase 2	Not yet recruiting	Dec 30, 2026	30	0 of 1 sites in the United States
NCT02066389	Phase 2	Completed	Jul 2, 2015	300	12 of 63 sites in the United States
NCT07727889	Phase 2	Active, not recruiting	Jul 1, 2027	50	0 of 1 sites in the United States
NCT06660693	Phase 3	Recruiting	May 1, 2027	134	0 of 1 sites in the United States
NCT05609630	Phase 3	Recruiting	Jun 1, 2029	90	6 of 45 sites in the United States
NCT04927975	Phase 2	Completed	Jan 13, 2023	185	20 of 35 sites in the United States
NCT05889182	Phase 3	Active, not recruiting	Mar 1, 2028	1328	87 of 285 sites in the United States
NCT03682705	Phase 2	Completed	Mar 26, 2020	242	78 of 115 sites in the United States
NCT03086343	Phase 3	Completed	Jun 13, 2019	657	44 of 161 sites in the United States
NCT02706847	Phase 3	Completed	Apr 3, 2017	499	103 of 188 sites in the United States
NCT05601882	Phase 3	Completed	Mar 19, 2024	920	58 of 257 sites in the United States
NCT06461897	Phase 3	Active, not recruiting	Nov 1, 2029	699	31 of 150 sites in the United States
NCT03104400	Phase 3	Completed	Sep 26, 2019	1705	114 of 345 sites in the United States
NCT06701331	Phase 3	Active, not recruiting	Jan 1, 2027	99	0 of 25 sites in the United States
NCT02706951	Phase 3	Completed	Oct 2, 2017	648	52 of 153 sites in the United States
NCT03345836	Phase 3	Completed	Aug 11, 2021	624	119 of 428 sites in the United States

On the calendar

Timeline

Registered trials

More from AbbVie